Joel A Sincavage

Array ( [id] => 6001807 [patent_doc_number] => 20110117646 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2011-05-19 [patent_title] => 'ANTISENSE MODULATION OF C-REACTIVE PROTEIN EXPRESSION' [patent_app_type] => utility [patent_app_number] => 13/019190 [patent_app_country] => US [patent_app_date] => 2011-02-01 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 25584 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0117/20110117646.pdf [firstpage_image] =>[orig_patent_app_number] => 13019190 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 8995018 [patent_doc_number] => 08518902 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2013-08-27 [patent_title] => 'Use of RNAi technology to inhibit ASIC3' [patent_app_type] => utility [patent_app_number] => 13/017738 [patent_app_country] => US [patent_app_date] => 2011-01-31 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 20 [patent_figures_cnt] => 3 [patent_no_of_words] => 21542 [patent_no_of_claims] => 3 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 43 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13017738 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 6178126 [patent_doc_number] => 20110178156 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2011-07-21 [patent_title] => 'Method of suppressing pRb deficiency-induced tumor formation' [patent_app_type] => utility [patent_app_number] => 12/930861 [patent_app_country] => US [patent_app_date] => 2011-01-19 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 10 [patent_figures_cnt] => 10 [patent_no_of_words] => 9824 [patent_no_of_claims] => 16 [patent_no_of_ind_claims] => 5 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0178/20110178156.pdf [firstpage_image] =>[orig_patent_app_number] => 12930861 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 6102706 [patent_doc_number] => 20110166199 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2011-07-07 [patent_title] => 'RNAi COMPOUND TARGETED TO THROMBOSPONDIN-1 AND APPLICATIONS THEREOF' [patent_app_type] => utility [patent_app_number] => 12/985684 [patent_app_country] => US [patent_app_date] => 2011-01-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 3 [patent_figures_cnt] => 3 [patent_no_of_words] => 3590 [patent_no_of_claims] => 29 [patent_no_of_ind_claims] => 4 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0166/20110166199.pdf [firstpage_image] =>[orig_patent_app_number] => 12985684 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 8490175 [patent_doc_number] => 20120289583 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2012-11-15 [patent_title] => 'TREATMENT OF INSULIN RECEPTOR SUBSTRATE 2 (IRS2) RELATED DISEASES BY INHIBITION OF NATURAL ANTISENSE TRANSCRIPT TO IRS2 AND TRANSCRIPTION FACTOR E3 (TFE3)' [patent_app_type] => utility [patent_app_number] => 13/519518 [patent_app_country] => US [patent_app_date] => 2010-12-30 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 2 [patent_figures_cnt] => 2 [patent_no_of_words] => 25943 [patent_no_of_claims] => 37 [patent_no_of_ind_claims] => 10 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13519518 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 8028303 [patent_doc_number] => 08143233 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2012-03-27 [patent_title] => 'RNA aptamers and methods for identifying the same' [patent_app_type] => utility [patent_app_number] => 12/971695 [patent_app_country] => US [patent_app_date] => 2010-12-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 30 [patent_figures_cnt] => 45 [patent_no_of_words] => 31353 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 42 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] => patents/08/143/08143233.pdf [firstpage_image] =>[orig_patent_app_number] => 12971695 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 5973203 [patent_doc_number] => 20110152349 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2011-06-23 [patent_title] => 'COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF IL-18 GENES' [patent_app_type] => utility [patent_app_number] => 12/967432 [patent_app_country] => US [patent_app_date] => 2010-12-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 59 [patent_figures_cnt] => 59 [patent_no_of_words] => 17819 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0152/20110152349.pdf [firstpage_image] =>[orig_patent_app_number] => 12967432 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 6186706 [patent_doc_number] => 20110124708 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2011-05-26 [patent_title] => 'RNAI-MEDIATED INHIBITION OF OCULAR HYPERTENSION TARGETS' [patent_app_type] => utility [patent_app_number] => 12/967121 [patent_app_country] => US [patent_app_date] => 2010-12-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 1 [patent_figures_cnt] => 1 [patent_no_of_words] => 19154 [patent_no_of_claims] => 26 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0124/20110124708.pdf [firstpage_image] =>[orig_patent_app_number] => 12967121 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 8381455 [patent_doc_number] => 20120225088 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2012-09-06 [patent_title] => 'COMPOSITIONS AND METHODS FOR TREATING CANCER AND OTHER DISEASES' [patent_app_type] => utility [patent_app_number] => 13/510221 [patent_app_country] => US [patent_app_date] => 2010-11-16 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 14 [patent_figures_cnt] => 14 [patent_no_of_words] => 17521 [patent_no_of_claims] => 49 [patent_no_of_ind_claims] => 13 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13510221 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 9016506 [patent_doc_number] => 20130231470 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2013-09-05 [patent_title] => 'DEFIBROTIDE FOR USE IN PROPHYLAXIS AND/OR TREATMENT OF GRAFT VERSUS HOST DISEASE (GVHD)' [patent_app_type] => utility [patent_app_number] => 13/884102 [patent_app_country] => US [patent_app_date] => 2010-11-12 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 4906 [patent_no_of_claims] => 10 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13884102 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 8495498 [patent_doc_number] => 20120294905 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2012-11-22 [patent_title] => 'Lipid Formulated Compositions And Methods For Inhibiting Expression Of Transthyretin (TTR)' [patent_app_type] => utility [patent_app_number] => 13/503843 [patent_app_country] => US [patent_app_date] => 2010-11-03 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 26 [patent_figures_cnt] => 26 [patent_no_of_words] => 46797 [patent_no_of_claims] => 24 [patent_no_of_ind_claims] => 8 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13503843 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 6054500 [patent_doc_number] => 20110110860 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2011-05-12 [patent_title] => 'MODULATION OF LDL RECEPTOR GENE EXPRESSION WITH DOUBLE-STRANDED RNAS TARGETING THE LDL RECEPTOR GENE PROMOTER' [patent_app_type] => utility [patent_app_number] => 12/938253 [patent_app_country] => US [patent_app_date] => 2010-11-02 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 43 [patent_figures_cnt] => 43 [patent_no_of_words] => 23429 [patent_no_of_claims] => 30 [patent_no_of_ind_claims] => 12 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0110/20110110860.pdf [firstpage_image] =>[orig_patent_app_number] => 12938253 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 8305908 [patent_doc_number] => 08227443 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2012-07-24 [patent_title] => 'Silencing of CSN5 gene expression using interfering RNA' [patent_app_type] => utility [patent_app_number] => 12/903558 [patent_app_country] => US [patent_app_date] => 2010-10-13 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 13 [patent_figures_cnt] => 30 [patent_no_of_words] => 45375 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 50 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 12903558 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 7696046 [patent_doc_number] => 20110230544 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2011-09-22 [patent_title] => 'MODULATION OF C-REACTIVE PROTEIN EXPRESSION' [patent_app_type] => utility [patent_app_number] => 12/902051 [patent_app_country] => US [patent_app_date] => 2010-10-11 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 49452 [patent_no_of_claims] => 34 [patent_no_of_ind_claims] => 9 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0230/20110230544.pdf [firstpage_image] =>[orig_patent_app_number] => 12902051 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 8708650 [patent_doc_number] => 20130065939 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2013-03-14 [patent_title] => 'COMPOSITIONS AND METHODS FOR SILENCING GENES EXPRESSED IN CANCER' [patent_app_type] => utility [patent_app_number] => 13/497789 [patent_app_country] => US [patent_app_date] => 2010-09-23 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 70 [patent_figures_cnt] => 70 [patent_no_of_words] => 103039 [patent_no_of_claims] => 22 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13497789 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10155986 [patent_doc_number] => 09187746 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2015-11-17 [patent_title] => 'Dual targeting siRNA agents' [patent_app_type] => utility [patent_app_number] => 13/497226 [patent_app_country] => US [patent_app_date] => 2010-09-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 6 [patent_figures_cnt] => 6 [patent_no_of_words] => 50182 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 98 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13497226 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 6096081 [patent_doc_number] => 20110003307 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2011-01-06 [patent_title] => 'METHODS FOR PRODUCING INTERFERING RNA MOLECULES IN MAMMALIAN CELLS AND THERAPEUTIC USES FOR SUCH MOLECULES' [patent_app_type] => utility [patent_app_number] => 12/881509 [patent_app_country] => US [patent_app_date] => 2010-09-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 8 [patent_figures_cnt] => 8 [patent_no_of_words] => 7697 [patent_no_of_claims] => 8 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0003/20110003307.pdf [firstpage_image] =>[orig_patent_app_number] => 12881509 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 9662313 [patent_doc_number] => 08809289 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2014-08-19 [patent_title] => 'Double-stranded nucleic acid molecule, cancer cell proliferation inhibitor and pharmaceutical agent suitable for prevention or treatment of cancer' [patent_app_type] => utility [patent_app_number] => 12/879305 [patent_app_country] => US [patent_app_date] => 2010-09-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 13 [patent_figures_cnt] => 29 [patent_no_of_words] => 10289 [patent_no_of_claims] => 17 [patent_no_of_ind_claims] => 8 [patent_words_short_claim] => 70 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 12879305 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 5929954 [patent_doc_number] => 20110039913 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2011-02-17 [patent_title] => 'ANTISENSE MODULATION OF HYDROXYSTEROID 11-BETA DEHYDROGENASE 1 EXPRESSION' [patent_app_type] => utility [patent_app_number] => 12/860181 [patent_app_country] => US [patent_app_date] => 2010-08-20 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 29972 [patent_no_of_claims] => 25 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0039/20110039913.pdf [firstpage_image] =>[orig_patent_app_number] => 12860181 [rel_patent_id] =>[rel_patent_doc_number] =>)